Ruth Ruddle

1.8k total citations
23 papers, 652 citations indexed

About

Ruth Ruddle is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ruth Ruddle has authored 23 papers receiving a total of 652 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 8 papers in Cancer Research and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ruth Ruddle's work include Cancer, Hypoxia, and Metabolism (6 papers), PI3K/AKT/mTOR signaling in cancer (6 papers) and Biochemical and Molecular Research (4 papers). Ruth Ruddle is often cited by papers focused on Cancer, Hypoxia, and Metabolism (6 papers), PI3K/AKT/mTOR signaling in cancer (6 papers) and Biochemical and Molecular Research (4 papers). Ruth Ruddle collaborates with scholars based in United Kingdom, United States and Germany. Ruth Ruddle's co-authors include Florence I. Raynaud, Paul Workman, Suzanne A. Eccles, Melanie Valenti, Michelle D. Garrett, Alexis de Haven Brandon, Ian Collins, John Caldwell, Wynne Aherne and Martin Rowlands and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Ruth Ruddle

21 papers receiving 646 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ruth Ruddle United Kingdom	12	409	137	99	98	79	23	652
Chris J. Novotny United States	9	642 1.6×	179 1.3×	131 1.3×	82 0.8×	78 1.0×	10	829
André Richters Germany	17	480 1.2×	144 1.1×	212 2.1×	111 1.1×	44 0.6×	24	776
Alexis de Haven Brandon United Kingdom	12	424 1.0×	179 1.3×	70 0.7×	122 1.2×	81 1.0×	22	595
Christina Esdar Germany	15	460 1.1×	182 1.3×	86 0.9×	45 0.5×	82 1.0×	38	698
Angela Hayes United Kingdom	15	484 1.2×	259 1.9×	75 0.8×	61 0.6×	69 0.9×	33	659
David Xu United States	14	318 0.8×	140 1.0×	55 0.6×	74 0.8×	74 0.9×	30	637
Jennifer M. Shipman United States	11	378 0.9×	128 0.9×	95 1.0×	123 1.3×	51 0.6×	13	539
Lora A. Tucker United States	13	326 0.8×	242 1.8×	61 0.6×	88 0.9×	84 1.1×	15	577
Morgan Pellerano France	12	337 0.8×	213 1.6×	104 1.1×	40 0.4×	119 1.5×	18	549
Theonie Anastassiadis United States	5	602 1.5×	181 1.3×	82 0.8×	58 0.6×	65 0.8×	6	817

Countries citing papers authored by Ruth Ruddle

Since Specialization

Citations

This map shows the geographic impact of Ruth Ruddle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth Ruddle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth Ruddle more than expected).

Fields of papers citing papers by Ruth Ruddle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruth Ruddle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth Ruddle. The network helps show where Ruth Ruddle may publish in the future.

Co-authorship network of co-authors of Ruth Ruddle

This figure shows the co-authorship network connecting the top 25 collaborators of Ruth Ruddle. A scholar is included among the top collaborators of Ruth Ruddle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruth Ruddle. Ruth Ruddle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zachariou, Athanasios, Sudhir Venkatesan, Xiaolin Hu, et al.. (2025). 85P: Phase I results from the phase I/II POTENT trial of tepotinib and pembrolizumab in non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 20(3). S62–S63.

Pacey, Simon, Simon Rodney, Ruth Ruddle, et al.. (2024). Abstract CT111: Pharmacokinetic and pharmacodynamic evaluation of NXP800, a novel GCN2 activator, in a first in human clinical trial. Cancer Research. 84(7_Supplement). CT111–CT111. 1 indexed citations

Banerji, Udai, Simon Pacey, Simon Rodney, et al.. (2023). Abstract B044: Results of a phase 1 dose escalation clinical trial of NXP800, a novel GCN2 activator, in patients with advanced or metastatic solid tumors. Molecular Cancer Therapeutics. 22(12_Supplement). B044–B044. 1 indexed citations

Coker, Elizabeth A., Adam Stewart, Buğra Özer, et al.. (2022). Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes. Molecular Cancer Therapeutics. 21(6). 1020–1029. 8 indexed citations

Kumar, Rajiv, Dionysis Papadatos-Pastos, Joaquı́n Mateo, et al.. (2020). First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors. Clinical Cancer Research. 26(18). 4777–4784. 52 indexed citations

Pál, Ákos, Yasmin J. Asad, Ruth Ruddle, et al.. (2020). Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients are associated with NOS regulation. Metabolomics. 16(4). 50–50. 3 indexed citations

Banerji, Udai, Alvaro Ingles Garces, Vasiliki Michalarea, et al.. (2017). An investigator-initiated phase I study of ONX-0801, a first-in-class alpha folate receptor targeted, small molecule thymidylate synthase inhibitor in solid tumors.. Journal of Clinical Oncology. 35(15_suppl). 2503–2503. 12 indexed citations

Yogev, Orli, Karen Barker, Gilberto S. Almeida, et al.. (2016). p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance. Cancer Research. 76(10). 3025–3035. 32 indexed citations

Michalarea, Vasiliki, José Ramón Antúnez López, David Lorente, et al.. (2015). 343 Translational phase I trial combining the AKT inhibitor AZD5363 (AZD) and PARP inhibitor Olaparib (Ola) in advanced cancer patients (pts). European Journal of Cancer. 51. S68–S68. 1 indexed citations

10.

Roda, Desamparados, Han Hsi Wong, Elena Geuna, et al.. (2014). TAX-TORC: A phase I trial of the combination of AZD2014 (dual mTORC1/mTORC2 inhibitor) and weekly paclitaxel in patients with solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 2607–2607. 2 indexed citations

11.

Kumar, Rajiv, Joaquı́n Mateo, Alan D. Smith, et al.. (2014). First-in-human, first-in-class phase 1 study of a novel oral multi-AGC kinase inhibitor AT13148 in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 2554–2554. 9 indexed citations

12.

Renshaw, Jane, Kathryn R. Taylor, Ryan T. Bishop, et al.. (2013). Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo. Clinical Cancer Research. 19(21). 5940–5951. 110 indexed citations

13.

Ewan, Kenneth, Bożena Pająk, Mark Stubbs, et al.. (2010). A Useful Approach to Identify Novel Small-Molecule Inhibitors of Wnt-Dependent Transcription. Cancer Research. 70(14). 5963–5973. 86 indexed citations

14.

Yap, Timothy A., Mike I. Walton, Melanie Valenti, et al.. (2010). Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930. Molecular Cancer Therapeutics. 10(2). 360–371. 59 indexed citations

15.

McHardy, Tatiana, John Caldwell, Kwai-Ming J. Cheung, et al.. (2010). Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt). Journal of Medicinal Chemistry. 53(5). 2239–2249. 67 indexed citations

16.

Payne, Geoffrey S., Ruth Ruddle, Florence I. Raynaud, et al.. (2009). A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy. British Journal of Cancer. 101(11). 1860–1868. 27 indexed citations

17.

Banerji, Udai, Swee Y. Sharp, Melanie Valenti, et al.. (2008). An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. Cancer Chemotherapy and Pharmacology. 62(5). 769–778. 30 indexed citations

18.

Caldwell, John, Thomas G. Davies, Alastair Donald, et al.. (2008). Identification of 4-(4-Aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as Selective Inhibitors of Protein Kinase B through Fragment Elaboration. Journal of Medicinal Chemistry. 51(7). 2147–2157. 74 indexed citations

19.

Wilsher, Nicola E., Ruth Ruddle, Yvette Newbatt, et al.. (2007). The Phosphoinositide-Specific Phospholipase C Inhibitor U73122 (1-(6-((17β-3-Methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione) Spontaneously Forms Conjugates with Common Components of Cell Culture Medium. Drug Metabolism and Disposition. 35(7). 1017–1022. 28 indexed citations

20.

Benepal, T., Ann L. Jackman, L Pyle, et al.. (2005). A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignancies. British Journal of Cancer. 93(8). 868–875. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact